Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117268 | 0.82 | MAOA (0.44) | RAB9ASMN1; SMN2PDE10AMAOAMAOB | |
| SCHEMBL2644955 | 0.81 | MAOA (0.39) | RAB9ATP53SMN1; SMN2PDE10AMAOA | |
| SCHEMBL2644959 | 0.81 | MAOA (0.39) | RAB9ATP53SMN1; SMN2PDE10AMAOA | |
| SCHEMBL12460725 | 0.81 | MAOA (0.36) | RAB9ASMN1; SMN2PDE10AMAOAMAOB | |
| SCHEMBL29407430 | 0.81 | MAOA (0.36) | RAB9ASMN1; SMN2PDE10AMAOAMAOB | |
| SCHEMBL23576574 | 0.81 | EPHX2 (0.41) | RAB9ASMN1; SMN2PDE10AMAOAMAOB | |
| SCHEMBL1557876 | 0.81 | MAOA (0.36) | RAB9ASMN1; SMN2PDE10AMAOAMAOB | |
| SCHEMBL26421438 | 0.79 | CCR1 (0.44) | CCR1CCR5CCR8HDAC6RAB9A | |
| SCHEMBL13771819 | 0.78 | NPC1 (0.44) | RAB9ATP53SMN1; SMN2PDE10AMAOA | |
| SCHEMBL19245816 | 0.78 | LMNA (0.38) | RAB9ATP53SMN1; SMN2PDE10AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3513793-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3196202-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-9090561-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8507481-B2 | Benzoxazine oxazolidinone compounds, preparation methods and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-13 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130123249-A1 | NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | NANJING CHANGAO PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LIMITED (CN) | 2013-05-16 | — | — | US | disclosed |
| EP-2578591-A1 | NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011147259-A1 | NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 中国科学院上海药物研究所 (CN) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010047737-A2 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CCR1 1106/4885CCR5 1435/4885CCR8 1709/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CCR1 1106/4885CCR5 1435/4885CCR8 1709/4885 |
| US-20130123249-A1 | NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | XDH, OXA1L, CYP3A5 | CCR1 3588/4885CCR5 1353/4885CCR8 3050/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CCR1 1106/4885CCR5 1435/4885CCR8 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.